|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.12 USD | -0.04% |
|
+2.16% | +80.89% |
| Jul. 09 | Immucell Corporation Reports Preliminary Unaudited Sales Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| May. 15 | ImmuCell Corporation, Q1 2026 Earnings Call, May 15, 2026 |
Business description: ImmuCell Corporation

Number of employees: 73
Sales by Activity: ImmuCell Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Scours | - | 18.41M | 17.29M | 26.31M | 27.45M |
Mastitis | - | 155K | 178K | 179K | 196K |
Biotechnology | 19.24M | - | - | - | - |
Other | - | 1.46K | - | - | - |
Geographical breakdown of sales: ImmuCell Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 16.62M | 17.02M | 15.95M | 22.89M | 24.39M |
Other | 2.62M | 1.55M | 1.52M | 3.6M | 3.25M |
Executive Committee: ImmuCell Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 2025-10-31 | |
Timothy Fiori
DFI | Director of Finance/CFO | 47 | 2025-04-06 |
| Comptroller/Controller/Auditor | - | - |
Composition of the Board of Directors: ImmuCell Corporation
| Director | Title | Age | Since |
|---|---|---|---|
David Tomsche
CHM | Chairman | 69 | 2013-11-30 |
Paul Wainman
BRD | Director/Board Member | 61 | 2014-03-30 |
Gloria Basse
BRD | Director/Board Member | 66 | 2020-06-09 |
| Director/Board Member | 54 | 2025-10-31 | |
Kathy Turner
BRD | Director/Board Member | 62 | 2026-03-31 |
| Director/Board Member | 64 | 2026-04-14 | |
Anthony DiMarco
BRD | Director/Board Member | 63 | 2026-04-14 |
Company details: ImmuCell Corporation

Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.04% | +2.16% | +68.56% | +109.12% | 101M | ||
| +0.85% | -0.80% | +54.84% | +163.70% | 1,051B | ||
| +1.23% | -1.53% | +55.26% | +59.07% | 609B | ||
| +0.04% | +2.58% | +32.96% | +88.75% | 450B | ||
| +0.78% | -0.71% | +30.04% | +24.61% | 330B | ||
| +1.41% | +0.58% | +33.92% | +47.20% | 284B | ||
| -0.27% | -1.87% | +22.13% | +23.47% | 263B | ||
| -1.76% | +2.37% | -22.19% | -38.45% | 223B | ||
| -1.42% | +0.80% | +22.81% | +60.77% | 198B | ||
| -1.48% | +3.43% | +23.42% | +73.31% | 167B | ||
| Average | -0.11% | +0.70% | +32.17% | +61.15% | 357.52B | |
| Weighted average by Cap. | +0.22% | +0.02% | +37.75% | +81.49% |
- Stock Market
- Stocks
- ICCC Stock
- Company ImmuCell Corporation
Select your edition
All financial news and data tailored to specific country editions

















